SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for a subcutaneous ...
Johnson & Johnson JNJ announced that it has submitted a regulatory filing with the FDA seeking approval for the use of a ...
The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...
The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...
Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...
Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...
Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a ...
Tremfya (guselkumab) is a prescription drug that’s used to treat certain autoimmune conditions, including plaque psoriasis. Tremfya can cause side effects that range from mild to serious.
Tremfya (guselkumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as plaque psoriasis. The drug is available as an injection given under the skin or as an IV ...